GlobeNewswire Inc | Jun 1, 2021 04:01PM EDT

June 01, 2021

HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present atthe Goldman Sachs 42nd Annual Global Healthcare ConferenceonTuesday, June 8, 2021 at 9:40 a.m. Eastern Time.

A live webcast of Kiniksas presentation will be accessible through the Investors & Media section of the companys website at www.kiniksa.com. A replay of the webcast will be available on Kiniksas website for 14 days following the conference.

About KiniksaKiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksas portfolio of assets, ARCALYST (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visitwww.kiniksa.com.

ARCALYSTis a registered trademark ofRegeneron Pharmaceuticals,Inc.

Every Second Counts!

Kiniksa Investor and Media ContactRachel Frank(339) 970-9437rfrank@kiniksa.com